Neurosense Therapeutics Ltd. (NRSN) has released an update.
NeuroSense Therapeutics Ltd. has announced the successful completion of the in-life phase of a nine-month non-rodent toxicity study for their drug candidate, PrimeC. This marks a significant step in the drug’s development, evidencing a promising safety profile that aligns with the company’s regulatory strategy. The positive outcomes from the study could potentially boost investor confidence in the company’s future prospects.
For further insights into NRSN stock, check out TipRanks’ Stock Analysis page.
